HRP20240338T1 - Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 - Google Patents
Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 Download PDFInfo
- Publication number
- HRP20240338T1 HRP20240338T1 HRP20240338TT HRP20240338T HRP20240338T1 HR P20240338 T1 HRP20240338 T1 HR P20240338T1 HR P20240338T T HRP20240338T T HR P20240338TT HR P20240338 T HRP20240338 T HR P20240338T HR P20240338 T1 HRP20240338 T1 HR P20240338T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- specifically binds
- cancer
- cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 230000008102 immune modulation Effects 0.000 title 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 25
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 25
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 7
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 6
- 210000005008 immunosuppressive cell Anatomy 0.000 claims 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000003101 oviduct Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000024558 digestive system cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 210000002707 regulatory b cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Protutijelo koje specifično veže CD38, naznačeno time, da je za uporabu u liječenju pacijenta koji ima solidni tumor, i time, da obuhvaća VH od SEQ ID NO: 4 i VL od SEQ ID NO: 5, pri čemu je protutijelo IgG1 izotipa.
2. Protutijelo koje specifično veže CD38 za uporabu prema patentnom zahtjevu 1, naznačeno time, da protutijelo sadrži aminokiselinu teškog lanca od SEQ ID NO: 12, i aminokiselinu lakog lanca od SEQ ID NO: 13.
3. Protutijelo koje specifično veže CD38 za uporabu prema patentnom zahtjevu 1, naznačeno time, da protutijelo je IgG1κ izotipa.
4. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time, da solidni tumor je melanom, rak pluća, rak skvamoznih ne-malih stanica pluća (NSCLC), ne-skvamozni NSCLC, kolorektalni rak, rak prostate, kastracijski rezistentan rak prostate, rak abdomena, rak jajnika, rak želuca, rak jetre, rak gušterače, rak štitnjače, karcinom skvamoznih stanica glave i vrata, karcinom jednjaka ili gastrointestinalnog trakta, rak dojke, rak jajovoda (falopijevih tuba), rak mozga, rak uretre, rak genitourinarnog sustava, endometrioza, rak cerviksa ili metastatske lezije raka.
5. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time, da solidni tumor nema ekspresiju CD38 koja se može prepoznati.
6. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da protutijelo koje specifično veže CD38 izaziva imunosni odgovor kod pacijenta, pri čemu imunosni odgovor je odgovor efektorske T stanice (Teff), gdje je Teff odgovor posredovan putem CD8+ T stanica, i pritom Teff odgovor predstavlja povećanje broja CD8+ T stanica.
7. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da protutijelo koje specifično veže CD38 inhibira djelovanje imunosupresorske stanice, pri čemu:
a. imunosupresorska stanica je regulacijska T stanica (Treg), pri čemu Treg je CD3+CD4+CD25+CD127dim T stanica, pri čemu Treg eksprimira CD38, gdje se djelovanje Treg inhibira pomoću usmrćivanja Treg, i pri čemu je usmrćivanje Treg posredovano putem o protutijelu ovisne stanične citotoksičnosti (ADCC); ili
b. imunosupresorska stanica je mijeloidno izvedena supresorska stanica (MDSC), pri čemu MDSC je CD11b+HLADR-CD14-CD33+CD15+ stanica, gdje CD11b+HLADR-CD14-CD33+CD15+ stanica eksprimira CD38, dok se djelovanje MDSC inhibira pomoću usmrćivanja MDSC, i pri čemu je usmrćivanje MDSC posredovano putem ADCC; ili
c. imunosupresorska stanica je regulacijska B stanica (Breg), pri čemu Breg je CD19+CD24+CD38+ stanica, gdje se djelovanje Breg inhibira pomoću usmrćivanja Breg, i pri čemu je usmrćivanje Breg posredovano putem ADCC; ili
d. imunosupresorska stanica obitava u perifernoj krvi.
8. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se protutijelo koje specifično veže CD38 primjenjuje u kombinaciji s drugim terapijskim sredstvom, tako da se kod drugog terapijskog sredstva radi o kemoterapeutskom sredstvu, ciljanoj terapiji protiv raka, standardnom lijeku za liječenje solidnog tumora, ili inhibitoru imunosne kontrolne točke.
9. Protutijelo koje specifično veže CD38 za uporabu prema patentnom zahtjevu 8, naznačeno time, da se kod inhibitora imunosne kontrolne točke radi o anti-PD-1 protutijelu, anti-PD-L1 protutijelu, anti-PD-L2 protutijelu, anti-LAG3 protutijelu, anti-TIM3 protutijelu, ili anti-CTLA-4 protutijelu.
10. Protutijelo koje specifično veže CD38 za uporabu prema patentnom zahtjevu 9, naznačeno time, da:
a. inhibitor imunosne kontrolne točke je anti-PD-1 protutijelo, opcionalno gdje anti-PD-1 protutijelo sadrži:
i. VH od SEQ ID NO: 22 i VL od SEQ ID NO: 23;
ii. VH od SEQ ID NO: 24 i VL od SEQ ID NO: 25;
iii. VH od SEQ ID NO: 32 i VL od SEQ ID NO: 33; ili
iv. VH od SEQ ID NO: 34 i VL od SEQ ID NO: 35; ili
b. inhibitor imunosne kontrolne točke je anti-PD-L1 protutijelo, opcionalno gdje anti-PD-L1 protutijelo sadrži:
i. VH od SEQ ID NO: 26 i VL od SEQ ID NO: 27;
ii. VH od SEQ ID NO: 28 i VL od SEQ ID NO: 29; ili
iii. VH od SEQ ID NO: 30 i VL od SEQ ID NO: 31; ili
c. inhibitor imunosne kontrolne točke je anti-PD-L2 protutijelo; ili
d. inhibitor imunosne kontrolne točke je anti-LAG3 protutijelo; ili
e. inhibitor imunosne kontrolne točke je anti-TIM-3 protutijelo, opcionalno gdje anti-TIM-3 protutijelo sadrži:
i. VH od SEQ ID NO: 36 i VL od SEQ ID NO: 37; ili
ii. VH od SEQ ID NO: 38 i VL od SEQ ID NO: 39.
11. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 8 do 10, naznačeno time, da se drugo terapijsko sredstvo primjenjuje istovremeno, uzastopno ili odvojeno.
12. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, naznačeno time, da se protutijelo koje specifično veže CD38, primjenjuje parentalno putem intravenske infuzije ili bolusne injekcije, intramuskularno, supkutano ili intraperitonealno.
13. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačeno time, da se protutijelo koje specifično veže CD38, primjenjuje intravenski.
14. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačeno time, da se protutijelo koje specifično veže CD38, primjenjuje supkutano.
15. Protutijelo koje specifično veže CD38 za uporabu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačeno time, da:
a. pacijent se liječi ili je bio liječen radijacijskom terapijom; i/ili
b. pacijent je već bio ili će biti podvrgnut kirurškom zahvatu.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184018P | 2015-06-24 | 2015-06-24 | |
| US201562249546P | 2015-11-02 | 2015-11-02 | |
| US201562250566P | 2015-11-04 | 2015-11-04 | |
| US201562263307P | 2015-12-04 | 2015-12-04 | |
| US201662331489P | 2016-05-04 | 2016-05-04 | |
| EP16815351.8A EP3313441B1 (en) | 2015-06-24 | 2016-06-24 | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| PCT/US2016/039165 WO2016210223A1 (en) | 2015-06-24 | 2016-06-24 | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240338T1 true HRP20240338T1 (hr) | 2024-05-24 |
Family
ID=57586547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240338TT HRP20240338T1 (hr) | 2015-06-24 | 2016-06-24 | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20160376373A1 (hr) |
| EP (2) | EP4385569A2 (hr) |
| JP (2) | JP7041519B2 (hr) |
| KR (1) | KR20180012864A (hr) |
| CN (1) | CN107921120A (hr) |
| AU (1) | AU2016281717B2 (hr) |
| BR (1) | BR112017027990A2 (hr) |
| CA (1) | CA2990620A1 (hr) |
| CL (2) | CL2017003275A1 (hr) |
| CO (1) | CO2017013332A2 (hr) |
| DK (1) | DK3313441T3 (hr) |
| DO (1) | DOP2017000305A (hr) |
| EA (1) | EA037548B1 (hr) |
| EC (1) | ECSP17084878A (hr) |
| FI (1) | FI3313441T3 (hr) |
| GT (1) | GT201700286A (hr) |
| HK (1) | HK1254942A1 (hr) |
| HR (1) | HRP20240338T1 (hr) |
| IL (1) | IL256248A (hr) |
| LT (1) | LT3313441T (hr) |
| MX (3) | MX2018000261A (hr) |
| MY (1) | MY193727A (hr) |
| NI (1) | NI201700170A (hr) |
| PE (1) | PE20181090A1 (hr) |
| PH (1) | PH12017502311A1 (hr) |
| PT (1) | PT3313441T (hr) |
| RS (1) | RS65347B1 (hr) |
| SI (1) | SI3313441T1 (hr) |
| SV (1) | SV2017005607A (hr) |
| UA (1) | UA124799C2 (hr) |
| WO (1) | WO2016210223A1 (hr) |
| ZA (1) | ZA201800476B (hr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296666A (en) * | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against 38cd for the treatment of multiple myeloma |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| CA3211863A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| WO2015145422A1 (en) | 2014-03-26 | 2015-10-01 | Scr Engineers Ltd | Livestock location system |
| AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| US10986817B2 (en) | 2014-09-05 | 2021-04-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| US11071279B2 (en) | 2014-09-05 | 2021-07-27 | Intervet Inc. | Method and system for tracking health in animal populations |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| AU2015353416C1 (en) | 2014-11-26 | 2022-01-27 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| ES2886523T3 (es) | 2014-11-26 | 2021-12-20 | Xencor Inc | Anticuerpos heterodiméricos que se unen a CD3 y CD20 |
| WO2016089960A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| SG11201803678SA (en) | 2015-11-03 | 2018-05-30 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| MX2018005550A (es) * | 2015-11-03 | 2019-07-18 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a tim-3 y sus usos. |
| US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
| WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| CN110520444A (zh) * | 2017-01-09 | 2019-11-29 | 拜奥穆尼克斯制药 | 用于制备多特异性抗体的多肽接头 |
| CN110536963A (zh) * | 2017-01-26 | 2019-12-03 | 桑格摩生物治疗股份有限公司 | B细胞工程改造 |
| US11780930B2 (en) | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| WO2019204462A2 (en) | 2018-04-17 | 2019-10-24 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| WO2019209712A1 (en) | 2018-04-22 | 2019-10-31 | Vence, Corp. | Livestock management system and method |
| MA53123A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| PE20211858A1 (es) | 2018-07-13 | 2021-09-21 | Genmab As | Variantes de anticuerpos anti-cd38 y sus usos |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| KR20210065146A (ko) * | 2018-09-27 | 2021-06-03 | 무스크 파운데이션 포 리서치 디벨롭먼트 | 암 치료를 위한 제약 조합물 |
| CN116548315A (zh) | 2018-10-10 | 2023-08-08 | 世亚工程设备有限公司 | 牲畜干乳方法和装置 |
| WO2020194241A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses |
| JP2023510397A (ja) | 2020-01-16 | 2023-03-13 | ジェンマブ エー／エス | Ｃｄ３８抗体の製剤およびその使用 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| IL275518B (en) | 2020-06-18 | 2021-10-31 | Scr Eng Ltd | Animal tag |
| USD990062S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| USD990063S1 (en) | 2020-06-18 | 2023-06-20 | S.C.R. (Engineers) Limited | Animal ear tag |
| KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| IL302630A (en) | 2020-11-25 | 2023-07-01 | Identigen Ltd | A system and method for tracking members of an animal population |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| JP2024503432A (ja) | 2021-01-14 | 2024-01-25 | モルフォシス・アーゲー | 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CN114805582B (zh) * | 2022-06-29 | 2022-10-04 | 上海恒润达生生物科技股份有限公司 | 抗Trop2纳米抗体及其用途 |
| WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| DK2177620T3 (en) | 2003-03-05 | 2015-01-26 | Halozyme Inc | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, use and pharmaceutical compositions comprising thereof |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| IL296666A (en) | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against 38cd for the treatment of multiple myeloma |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| CN106434683B (zh) | 2005-10-12 | 2020-03-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| WO2008037257A2 (en) * | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| MX2009010282A (es) | 2007-03-29 | 2009-10-12 | Genmab As | Anticuerpos biespecificos y metodos para su produccion. |
| PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
| EP2231904B1 (en) | 2007-12-19 | 2016-01-13 | Janssen Biotech, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
| EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2899209A1 (en) | 2008-04-29 | 2015-07-29 | Abbvie Inc. | Dual Variable Domain Immunoglobulins and uses thereof |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
| HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| DK2580243T3 (da) * | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| BR122022015975B1 (pt) * | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo |
| US9179480B2 (en) | 2012-07-24 | 2015-11-03 | Telefonaktiebolaget L M Ericsson (Publ) | Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| ES2621377T3 (es) * | 2012-11-05 | 2017-07-03 | Morphosys Ag | Anticuerpo marcado radiactivamente y usos del mismo |
| BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| US20140356318A1 (en) * | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| EP3004169B1 (en) | 2013-05-31 | 2023-03-22 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| RU2016101109A (ru) | 2013-07-15 | 2017-08-18 | Дзе Боард Оф Трастис Оф Дзе Лилэнд Стэнфорд Джуниор Юниверсити | Медицинское применение агонистов cd38 |
| WO2015067570A2 (en) * | 2013-11-06 | 2015-05-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
-
2016
- 2016-06-24 MX MX2018000261A patent/MX2018000261A/es unknown
- 2016-06-24 SI SI201631806T patent/SI3313441T1/sl unknown
- 2016-06-24 DK DK16815351.8T patent/DK3313441T3/da active
- 2016-06-24 KR KR1020187001612A patent/KR20180012864A/ko not_active Application Discontinuation
- 2016-06-24 LT LTEPPCT/US2016/039165T patent/LT3313441T/lt unknown
- 2016-06-24 MY MYPI2017704935A patent/MY193727A/en unknown
- 2016-06-24 BR BR112017027990-8A patent/BR112017027990A2/pt active Search and Examination
- 2016-06-24 AU AU2016281717A patent/AU2016281717B2/en active Active
- 2016-06-24 CA CA2990620A patent/CA2990620A1/en active Pending
- 2016-06-24 RS RS20240308A patent/RS65347B1/sr unknown
- 2016-06-24 PT PT168153518T patent/PT3313441T/pt unknown
- 2016-06-24 UA UAA201800631A patent/UA124799C2/uk unknown
- 2016-06-24 WO PCT/US2016/039165 patent/WO2016210223A1/en active Application Filing
- 2016-06-24 JP JP2017566768A patent/JP7041519B2/ja active Active
- 2016-06-24 CN CN201680048975.9A patent/CN107921120A/zh active Pending
- 2016-06-24 HR HRP20240338TT patent/HRP20240338T1/hr unknown
- 2016-06-24 PE PE2017002833A patent/PE20181090A1/es unknown
- 2016-06-24 EP EP24158614.8A patent/EP4385569A2/en active Pending
- 2016-06-24 EA EA201890131A patent/EA037548B1/ru unknown
- 2016-06-24 US US15/191,808 patent/US20160376373A1/en not_active Abandoned
- 2016-06-24 EP EP16815351.8A patent/EP3313441B1/en active Active
- 2016-06-24 FI FIEP16815351.8T patent/FI3313441T3/fi active
-
2017
- 2017-12-11 IL IL256248A patent/IL256248A/en unknown
- 2017-12-14 PH PH12017502311A patent/PH12017502311A1/en unknown
- 2017-12-19 CL CL2017003275A patent/CL2017003275A1/es unknown
- 2017-12-20 NI NI201700170A patent/NI201700170A/es unknown
- 2017-12-21 DO DO2017000305A patent/DOP2017000305A/es unknown
- 2017-12-22 CO CONC2017/0013332A patent/CO2017013332A2/es unknown
- 2017-12-22 SV SV2017005607A patent/SV2017005607A/es unknown
- 2017-12-26 GT GT201700286A patent/GT201700286A/es unknown
- 2017-12-26 EC ECIEPI201784878A patent/ECSP17084878A/es unknown
-
2018
- 2018-01-08 MX MX2021012133A patent/MX2021012133A/es unknown
- 2018-01-08 MX MX2021012134A patent/MX2021012134A/es unknown
- 2018-01-23 ZA ZA2018/00476A patent/ZA201800476B/en unknown
- 2018-11-02 HK HK18114045.6A patent/HK1254942A1/zh unknown
-
2019
- 2019-12-13 CL CL2019003657A patent/CL2019003657A1/es unknown
-
2022
- 2022-02-03 JP JP2022015442A patent/JP2022070892A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240338T1 (hr) | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 | |
| AU2016313404B2 (en) | PD-L1 ("programmed death-ligand 1") antibodies | |
| JP2016528195A5 (hr) | ||
| JP2019519499A5 (hr) | ||
| JP2020534250A5 (hr) | ||
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| JP2017533912A5 (hr) | ||
| JP2019515008A5 (hr) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017535257A5 (hr) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP2018512170A5 (hr) | ||
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| Gasser et al. | Therapeutic antibodies in cancer therapy | |
| HRP20160190T1 (hr) | Protutijela anti-igf | |
| JP2018508512A5 (hr) | ||
| JP2018518454A5 (hr) | ||
| JP2018508483A5 (hr) | ||
| JP2018501197A5 (hr) | ||
| RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2014158469A5 (hr) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2020129075A (ru) | Способы лечения рака с помощью анти-PD-1-антител и анти-CTLA4-антител | |
| RU2018102547A (ru) | Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака |